Medicare drug coverage

Rexulti: 2027 Medicare Part D coverage

5,495 of 5,495 Part D plans (100%) list Rexulti on their 2027 formulary, the plan's list of covered drugs (the same share as 2026). 98% of those require prior authorization, step therapy, or a quantity limit. Plan counts include both Medicare Advantage plans with drug coverage (5,172 MA-PD) and stand-alone drug plans (323 PDP).

License: a US government work, in the public domain (Public Domain Mark 1.0).

Data only, not plan advice. Confirm on Medicare.gov Plan Finder or 1-800-MEDICARE.

2027 compared with 2026

Rexulti is number 54 by total Medicare Part D spending in 2024 ($861 million). Plans that list it most often put it on tier 5 (a tier is the cost level a plan puts a drug on; a lower tier usually costs less). Counts use 7 RxNorm products for this name.

Rexulti Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it5,517 (100%)5,495 (100%)no change
Prior authorization (of plans that list it)1,690 (31%)1,601 (29%)-2 points
Step therapy (of plans that list it)92 (2%)84 (2%)no change
Quantity limit (of plans that list it)5,277 (96%)5,362 (98%)+2 points
Any of the three (of plans that list it)5,315 (96%)5,395 (98%)+2 points
Not listed or restricted (of all plans)5,316 (96%)5,395 (98%)+2 points

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

For pharmacies and agencies: check a whole drug list against 2027 formularies.

Upload your patient list or your book of clients and Rivvi checks each drug against the CMS 2027 formulary files, plan by plan, so you see tier changes and new limits before the next refill or open enrollment. Free to start. HIPAA BAA included.

Formulary tier

Rexulti formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 1163 (3%)123 (2%)
Tier 22 (0%)1 (0%)
Tier 356 (1%)0 (0%)
Tier 4284 (5%)1,074 (20%)
Tier 55,012 (91%)4,297 (78%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan IDs are in both files. 129 of them (3%) added prior authorization, step therapy, or a quantity limit for Rexulti, and 0 stopped listing it.

Rexulti: plans in both 2026 and 2027
Plan by planPlans
Same plan ID in both years4,380
Listed it in 2026, not in 20270 (0%)
Listed it in 2027, not in 20260 (0%)
Moved it to a higher tier161 (4%)
Added prior authorization38 (1%)
Added step therapy18 (0%)
Added a quantity limit73 (2%)
Added at least one of the three129 (3%)
Removed at least one of the three68 (2%)
Plan IDs new in 20271,115
2026 plan IDs not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Rexulti off the formulary or list it with prior authorization, step therapy, or a quantity limit. 40 states tie for the highest share, 100%; Maryland ranks last at 80%. The table breaks ties on the prior authorization or step therapy share.

States from most to least restrictive for Rexulti, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Montana27100%67%no change
2Pennsylvania324100%63%no change
3Michigan183100%62%no change
4Wyoming13100%62%no change
5West Virginia70100%51%no change
6Vermont14100%50%no change
7Utah53100%40%no change
8Florida549100%37%no change
9New Hampshire25100%36%no change
10Oklahoma81100%36%no change
11Kentucky123100%36%no change
12Alaska9100%33%no change
13Idaho45100%33%no change
14Kansas84100%32%no change
15Louisiana126100%32%no change
16Nevada100100%31%+4 points
17Minnesota63100%30%no change
18New Jersey74100%30%no change
19South Carolina91100%30%no change
20New Mexico68100%29%+5 points
21Arkansas86100%29%no change
22Maine52100%29%no change
23Mississippi105100%29%no change
24Delaware43100%28%no change
25Rhode Island29100%28%no change
26New York215100%27%no change
27North Carolina177100%26%no change
28Nebraska51100%25%no change
29Texas412100%25%+1 point
30Alabama115100%24%no change
31Illinois133100%24%no change
32Indiana140100%24%no change
33Missouri171100%23%no change
34Iowa64100%22%no change
35Arizona148100%20%+4 points
36Tennessee157100%17%no change
37North Dakota26100%15%no change
38South Dakota30100%13%no change
39Connecticut54100%13%+4 points
40Massachusetts92100%8%+23 points
41Wisconsin9799%34%no change
42Ohio17398%19%-1 point
43Washington11497%36%+1 point
44Virginia14596%34%no change
45Oregon9296%25%no change
46Georgia15195%27%no change
47Colorado10690%25%+3 points
48Hawaii5088%16%no change
49California39788%26%+13 points
50District of Columbia2186%19%-2 points
51Maryland4980%18%-4 points

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Rexulti off or restrict it.

Rexulti coverage by parent organization, 2027
Parent organization2027 plans ↑List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
BrightSpring Health Services, Inc.2100%100%100%no change0
Community Health Group2100%100%100%no change0
Community Health Plan of Washington2100%100%100%no change0
Denver Health and Hospital Authority2100%100%100%no change0
Elevance Health, Inc. & BCBSMA & BCBSRI & BCBSVT2100%100%100%no change0
Elite Health Systems, Inc.2100%100%100%no change0
Group Health Cooperative of Eau Claire2100%100%100%no change0
Hamaspik of Rockland County, Inc.2100%100%100%no change0
ISNP Holdings, LLC2100%100%100%no change0
Kansas Superior Select2100%100%100%no change0
Missouri Healthcare Advisors, LLC2100%100%100%no change0
MultiCare Health Systems2100%100%100%new in 20270
NEIGHBORHOOD HEALTH PLAN OF RHODE ISLAND2100%100%100%no change0
PrimeWest Rural MN Health Care Access Initiative2100%100%100%no change0
Regency ISNP Holdings LLC2100%100%100%no change0
Select Founders, LLC2100%100%100%no change0
Sentara Health Care (SHC)2100%100%100%no change0
South Country Health Alliance2100%100%100%no change0
The Regents of the University of California2100%100%100%no change0
Troy Holdings, Inc.2100%100%100%no change0
Associated Care Ventures, Inc.3100%100%100%no change0
Aultman Health Foundation3100%0%0%no change0
Banner Health3100%100%100%no change0
Bexar County Hospital District3100%100%100%no change0
Blue Cross Blue Shield of Nebraska3100%100%100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.